UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,357 Shares of Masimo Co. (NASDAQ:MASI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 6.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,471 shares of the medical equipment provider's stock after selling 8,357 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.21% of Masimo worth $14,996,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in MASI. NBC Securities Inc. raised its position in Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC raised its position in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. HHM Wealth Advisors LLC increased its holdings in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after buying an additional 125 shares during the period. Finally, Fifth Third Bancorp increased its holdings in shares of Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider's stock worth $88,000 after buying an additional 98 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Stock Up 0.2 %

Shares of Masimo stock traded up $0.40 during midday trading on Friday, hitting $169.79. The company had a trading volume of 253,379 shares, compared to its average volume of 513,913. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market capitalization of $9.09 billion, a P/E ratio of 117.10 and a beta of 1.01. The company has a 50 day moving average of $153.35 and a 200 day moving average of $131.52. Masimo Co. has a 52-week low of $101.35 and a 52-week high of $178.27.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same period last year, the business posted $0.63 EPS. The company's revenue was up 5.4% compared to the same quarter last year. On average, equities analysts predict that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MASI. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. Piper Sandler boosted their target price on Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. BTIG Research boosted their target price on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Raymond James raised Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target for the company in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $167.00.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.